Gloucester Pharmaceuticals To Present New Data From Two Studies On Romidepsin At ASCO
Gloucester Pharmaceuticals announced that results from two studies of romidepsin, its novel, cyclic peptide, histone deacetylase inhibitor under investigation for the treatment of hematologic malignancies, will be presented at the American Society of Clinical Oncology (ASCO) Annual Meeting in Orlando, Florida on Saturday, May 30, 2009.
More: continued here
Filed under: Blood on June 1st, 2009
You must be logged in to post a comment.